Nimedine (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem/cilastatin is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections.

• Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure in mixed aerobic‑anaerobic infections.
• Complicated urinary tract infections: eliminates resistant uropathogens to achieve resolution of infection.
• Complicated skin and soft tissue infections: targets Gram‑negative and Gram‑positive organisms for effective healing.
• Community‑acquired bacterial pneumonia: offers rapid bacterial clearance and symptom improvement.
• Severe sepsis: delivers broad coverage to control systemic infection and organ dysfunction.

• Imipenem binds to penicillin‑binding proteins, inhibiting the final stages of bacterial cell wall synthesis, which leads to cell lysis. Cilastatin, co‑administered, inhibits renal dehydropeptidase‑I, preventing enzymatic degradation of imipenem and thereby maintaining therapeutic plasma concentrations.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: localized skin erythema.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Injection site pain: discomfort at the infusion site.
• Headache: mild, transient.

Serious or Rare Side Effects

• Seizures: especially in patients with CNS disorders or renal impairment.
• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile colitis: antibiotic‑associated diarrhea.
• Acute renal failure: due to nephrotoxic interactions.
• Thrombocytopenia: low platelet count.
• Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy, assess patient-specific factors and monitor for adverse events.

• Renal function: adjust dosing in patients with impaired kidney function.
• Allergy: avoid in individuals with known hypersensitivity to β‑lactam antibiotics.
• Seizure risk: use cautiously in patients with a history of seizures or CNS disease.
• Drug interactions: review concomitant medications that may affect renal clearance or increase neurotoxicity.
• Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin may interact with several drugs; monitoring is essential.

Major Interactions (Avoid)

• Valproic acid: increased serum levels may cause toxicity.
• Cisplatin: additive nephrotoxicity risk.
• Probenecid: reduces renal clearance, raising drug concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Loop diuretics: may increase risk of renal impairment.
• Other β‑lactam antibiotics: potential additive toxicity, especially neurotoxicity.